HK Movers | Hengrui Pharma Stock Jumps 4% to New High After Gaining Approval for Clinical Trial of New Inhalation Drug
Reuters
Jul 10
Hengrui Pharma stock gained another 4% to new high as it has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received a "Drug Clinical Trial Approval Notification" for HRS-9821 inhalation powder.
This approval marks a significant milestone in the drug's development process, allowing it to proceed to clinical trials in accordance with the regulations of the People's Republic of China.
The company emphasizes the lengthy and complex journey from development to market, acknowledging the uncertainties that may impact medicinal product R&D and marketing. Jiangsu Hengrui remains committed to advancing this R&D project and will continue to provide updates on its progress as required by national stipulations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.